These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24565738)

  • 1. Use of drug-susceptibility testing for management of drug-resistant tuberculosis, Thailand, 2004-2008.
    Lam E; Nateniyom S; Whitehead S; Anuwatnonthakate A; Monkongdee P; Kanphukiew A; Inyaphong J; Sitti W; Chiengsorn N; Moolphate S; Kavinum S; Suriyon N; Limsomboon P; Danyutapolchai J; Sinthuwattanawibool C; Podewils LJ
    Emerg Infect Dis; 2014 Mar; 20(3):400-8. PubMed ID: 24565738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon.
    Noeske J; Voelz N; Fon E; Abena Foe JL
    BMC Res Notes; 2012 Mar; 5():160. PubMed ID: 22436423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of microscopic observation drug susceptibility assay for diagnosis of multidrug-resistant tuberculosis in Viet Nam.
    Dang TM; Nguyen TN; Wolbers M; Vo SK; Hoang TT; Nguyen HD; To MH; Vuong MB; Nguyen TP; Tran VQ; Nguyen TB; Vo TH; Nguyen TN; Dai VH; Phan TH; Nguyen HD; Farrar J; Caws M
    BMC Infect Dis; 2012 Mar; 12():49. PubMed ID: 22375832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP
    PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes.
    Yoshiyama T; Yanai H; Rhiengtong D; Palittapongarnpim P; Nampaisan O; Supawitkul S; Uthaivorawit W; Mori T
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):31-8. PubMed ID: 14974743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved treatment outcome of multidrug-resistant tuberculosis with the use of a rapid molecular test to detect drug resistance in China.
    Shi W; Davies Forsman L; Hu Y; Zheng X; Gao Y; Li X; Jiang W; Bruchfeld J; Diwan VK; Hoffner S; Xu B
    Int J Infect Dis; 2020 Jul; 96():390-397. PubMed ID: 32353546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008.
    Velásquez GE; Yagui M; Cegielski JP; Asencios L; Bayona J; Bonilla C; Jave HO; Yale G; Suárez C; Atwood S; Contreras CC; Shin SS
    Emerg Infect Dis; 2011 Mar; 17(3):432-40. PubMed ID: 21392434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
    Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA
    Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and associated risk factors of drug-resistant tuberculosis in Thailand: results from the fifth national anti-tuberculosis drug resistance survey.
    Kamolwat P; Nateniyom S; Chaiprasert A; Disratthakit A; Mahasirimongkol S; Yamada N; Smithtikarn S
    Trop Med Int Health; 2021 Jan; 26(1):45-53. PubMed ID: 32997863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological profile of patients with rifampicin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014-2018.
    Bahizi G; Majwala RK; Kisaka S; Nyombi A; Musisi K; Kwesiga B; Bulage L; Ario AR; Turyahabwe S
    Antimicrob Resist Infect Control; 2021 May; 10(1):76. PubMed ID: 33964986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microscopic-observation drug-susceptibility assay for the diagnosis of drug-resistant tuberculosis in Harare, Zimbabwe.
    Makamure B; Mhaka J; Makumbirofa S; Mutetwa R; Mupfumi L; Mason P; Metcalfe JZ
    PLoS One; 2013; 8(2):e55872. PubMed ID: 23409072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to second-line drug susceptibility testing results among patients with Rifampicin resistant tuberculosis after introduction of the Hain
    Timire C; Sandy C; Kumar AMV; Ngwenya M; Murwira B; Takarinda KC; Harries AD
    Int J Infect Dis; 2019 Apr; 81():236-243. PubMed ID: 30776546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant tuberculosis in Rawalpindi, Pakistan.
    Khurram M; Khaar HT; Fahim M
    J Infect Dev Ctries; 2012 Jan; 6(1):29-32. PubMed ID: 22240425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Has introduction of rapid drug susceptibility testing at diagnosis impacted treatment outcomes among previously treated tuberculosis patients in Gujarat, India?
    Dave P; Vadera B; Kumar AM; Chinnakali P; Modi B; Solanki R; Patel P; Patel P; Pujara K; Nimavat P; Shah A; Bharaswadkar S; Rade K; Parmar M; Nair SA
    PLoS One; 2015; 10(4):e0121996. PubMed ID: 25874545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of katG, inhA, rpoB and pncA in Mycobacterium tuberculosis isolates from MDR-TB risk patients in Thailand.
    Suthum K; Samosornsuk W; Samosornsuk S
    J Infect Dev Ctries; 2020 Mar; 14(3):268-276. PubMed ID: 32235087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests.
    Zetola NM; Modongo C; Moonan PK; Ncube R; Matlhagela K; Sepako E; Collman RG; Bisson GP
    J Infect Dis; 2014 Jun; 209(11):1754-63. PubMed ID: 24443546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017.
    Glasauer S; Altmann D; Hauer B; Brodhun B; Haas W; Perumal N
    PLoS One; 2019; 14(6):e0217597. PubMed ID: 31188848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.